ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "outcomes"

  • Abstract Number: 2403 • 2014 ACR/ARHP Annual Meeting

    From Early Arthritis Clinic to Remission Clinic: Short-Term Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in DMARD-Induced SDAI-Remission during Drug-Free Follow-up

    Antonio Manzo1, Francesca Benaglio1, Garifallia Sakellariou1, Martina Scarabelli1, Elisa Binda1, Barbara Vitolo1, Serena Bugatti1, Roberto Caporali2 and Carlomaurizio Montecucco1, 1Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, 2Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy

    Background/Purpose The introduction of DAS-driven intensive treatment strategies in early rheumatoid arthritis (RA) has considerably improved outcome and patients’ quality of life. Previous studies have…
  • Abstract Number: 375 • 2014 ACR/ARHP Annual Meeting

    Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab

    Martin J. Bergman1, Jeffrey Yourish2, Jinglan Pei2, Jenny Devenport2, William Reiss2 and Edward Keystone3, 1Taylor Hospital, Ridley Park, PA, 2Genentech, South San Francisco, CA, 3University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Based on treat-to-target guidelines, the goal of treatment should be remission. Definitions for remission recommended by the ACR/EULAR task force include joint counts and…
  • Abstract Number: 2153 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics and Outcomes in Synovial Fluid Culture ̵ Negative Septic Arthritis

    Sarah B. Lieber, Ziv Paz and Robert H. Shmerling, Beth Israel Deaconess Medical Center, Boston, MA

    Background/Purpose: Delays in diagnosis and treatment of septic arthritis may be associated with significant morbidity. While many patients with suspected or proven septic arthritis are…
  • Abstract Number: 2037 • 2014 ACR/ARHP Annual Meeting

    Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population

    Neil Accortt1, Mary Anthony1, Jennifer Schenfeld2, Travis Wheeling2, Anna Hassebroek2, Cynthia O'Malley1 and Michael Sprafka1, 1Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, 2Docs Global, Inc, North Wales, PA

    Background/Purpose: There is a dearth of information on the incidence rate of myasthenia gravis (MG) in the US and specifically among rheumatoid arthritis (RA) patients. …
  • Abstract Number: 1670 • 2014 ACR/ARHP Annual Meeting

    Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus

    María Galindo Izquierdo1, Esther Rodriguez-Almaraz1, Sabina Perez2, José M. Pego-Reigosa3, Jaime Calvo-Alen4, Francisco Javier López-Longo5, Iñigo Rúa-Figueroa6, Alejandro Olivé7, Víctor Martínez Taboada8, Paloma Vela Casasempere9, Mercedes Freire10, Javier Narváez11, Antonio Fernandez Nebro12, Jose Rosas13, Monica Ibanez Barcelo14, Esther Uriarte15, Eva Tomero16, Antonio Zea17, Maria Loreto Horcada18, Vicente Torrente19, Ivan Castellvi20, Joan Calvet21, Raúl Menor Almagro22, Mª Angeles Aguirre23, Enrique Raya24, Elvira Diez Alvarez25, Tomás Vázquez Rodríguez26, Paloma García de la Peña27, Atusa Movasat28, José Luis Andreu29, Patricia Richi30, Carlos Marras Fernandez-Cid31, Carlos Alberto Montilla Morales32, Blanca Hernández-Cruz33, José Luis Marenco de la Fuente34, Marian Gantes35, Eduardo Ucar36, Juan J. Alegre37, Javier Manero38, Jesús Ibañez Ruán39, Manuel Rodríguez-Gómez40, Victor Quevedo41, José Hernández Beiraín42 and Lucía Silva Fernández43, 1Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, 2Sociedad Española de Reumatología, Research Unit,, Madrid, Spain, 3Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, 4Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, 5Rheumatology, Hospital Gregorio Marañon, Rheumatology, Hospital Gregorio Marañon, Madrid, Spain, 6Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, 7Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 8Rheumatology, Marqués de Valdecilla, Santander, Spain, 9Hospital General de Alicante, Alicante, Spain, 10Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, 11Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 12Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, 13Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, 14H. Son Llatzer, Palma de Mallorca, Spain, 15Rheumatology, Hospital de Donosti, San Sebastian, Spain, 16Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 17Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, 18Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, 19Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, 20Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 21Hospital Parc Taulí, Barcelona, Spain, 22Rheumatology, Hospital de Jerez, Jerez de la Frontera, Spain, 23Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 24Rheumatology, University Hospital San Cecilio, Granada, Spain, 25Rheumatology, Leon Hospital, Leon, Spain, 26Rheumatology, Hospital Lucus Augusti, Lugo, Spain, 27Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, 28Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, 29Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, 30Hospital Infanta Sofía, Madrid, Spain, 31C/ Salvia 11, H. Arrixaca, Alicante, Spain, 32Rheumatology Department, Hospital Virgen de la Vega, Salamanca, Spain, 33Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, 34Hospital de Valme. Sevilla, Sevilla, Spain, 35Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, 36Hospital de Basurto, Rheumatology, Bilbao, Spain, 37Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, 38Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, 39POVISA, Rheumatology, Vigo, Spain, 40Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 41Rheumatology, Hospital de Monforte, Lugo, Spain, 42Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, 43Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain

    Background/Purpose To describe the profile of patients included in RELESSER with histologically confirmed lupus nephritis (LN). Methods RELESSER is a multicentre cross-sectional study, with information…
  • Abstract Number: 1524 • 2014 ACR/ARHP Annual Meeting

    Rituximab Done! What’s Next in RA?

    Ulrich A. Walker1, Veronika K. Jaeger1, Katerina Chatzidionysiou2, Merete Lund Hetland3,4, Ellen Margrethe Hauge3,4, Karel Pavelka5, Dan C. Nordström6, Helena Canhao7, Matija Tomsic8, Ronald van Vollenhoven2 and Cem Gabay9, 1Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, 2Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 4DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, 5Charles University, Prague, Czech Republic, Prague, Czech Republic, 6ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, Helsinki, Finland, 7Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal on behalf of the Rheumatic Diseases Portugal Register, Lisbon, Portugal, 8Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, 9University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland

    Background/Purpose The optimal strategy to use biologics after rituximab (RTX) in RA is unknown. We therefore aimed to evaluate the effectiveness of different biologics after…
  • Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting

    Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting

    Yomei Shaw1, Chung-Chou H. Chang2, Marc C. Levesque3, Julie M. Donohue4, Kaleb Michaud5,6 and Mark S. Roberts1, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 4Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 5National Data Bank for Rheumatic Diseases, Wichita, KS, 6Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
  • Abstract Number: 1436 • 2014 ACR/ARHP Annual Meeting

    Impact of Depression on Clinical and Social Outcomes in Patients with Rheumatoid Arthritis: Comparative Study in Germany and Brazil

    Harriet Morf1, Olga Malysheva2, G da Rocha3, Anna Beatriz Vargas3 and Christoph G. Baerwald2, 1Department of Internal Medicine, University Hospital, Leipzig, Germany, 2Rheumatology, University Hospital, Leipzig, Germany, 3Ambulatório de reumatologia da Policlínica Piquet Carneiro, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

    Background/Purpose Rheumatoid Arthritis (RA) can be associated with psychological disorders and especially depression. About 13 – 20 % of patients have clinical significant depression. It…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology